Hanisha Reddy Kukunoor
Hanisha Reddy Kukunoor has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Mohammed Abdul Mateen
Department of Internal Medicine, Shadan Institute of Medical Sciences, Teaching Hospital and Research Centre, Hyderabad, India
2 shared publications - Aayush Sangwan
Department of Internal Medicine, NCR Institute of Medical Sciences, Meerut, India
1 shared publication Adithya Andanappa
Department of Internal Medicine, Mysore Medical College and Research Institute, Mysore, India
1 shared publication- Adithya Andanappa
Department of Internal Medicine, Mysore Medical College and Research Institute, Mysore, India
1 shared publication - Akanksha Singh
Department of Internal Medicine, Washington University of Health and Science, San Pedro, Belize
1 shared publication - Anusha Garapati
Department of Internal Medicine, College of Medical Sciences, Bharatpur, Nepal
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3695-3699
Early recognition and successful management of dermatomyositis-systemic lupus erythematosus overlap syndrome: case study of a young adult
Introduction and importance: An overlap syndrome is a condition when there is coexistence of two or more autoimmune connective tissue disease, which is very rare and diagnostically challenging. Dermatomyositis is an autoimmune condition that presents with skin manifestations, progressive muscular weakness, and inflammation. Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune condition mainly affecting skin, joints, kidneys, and brain. Early recognition and therapeutic intervention are necessary in overlap syndromes to prevent the patient from having severe cardiopulmonary problems. Case presentation: This is a case of a 32-year-old woman diagnosed with SLE who developed progressive muscle weakness (3/5 strength proximally) and a distinctive rash, classic signs of dermatomyositis from last 2 months. Laboratory tests have shown elevated creatine kinase (3500 U/l), positive ANA (1:640), anti-dsDNA, and anti-Jo-1 antibodies, along with visible myopathic alterations on electromyographs; unique results on muscle and skin biopsies were all confirmed by investigations. Clinical discussion: After confirming the diagnosis of dermatomyositis, the patient condition was managed by high dose corticosteroids (prednisolone 1 mg/kg/day), intravenous immunoglobulin for severe muscle weakness, methotrexate, high-dose corticosteroids, and physical therapy. Conclusion: This case highlights the complexity of diagnosis in distinguishing the true dermatomyositis from SLE associated inflammatory myopathy in young adults. It emphasizes the importance of early recognition of DM-SLE overlap syndrome through targeted investigations integrating clinical, serological, and histopathological assessment; that can alter the disease trajectory. The case emphasizes the importance of maintaining high clinical suspicion in patients with autoimmune diseases while guiding the immunosuppressive therapy.
- 27 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3695-3699
Open AccessEarly recognition and successful management of dermatomyositis-systemic lupus erythematosus overlap syndrome: case study of a young adult
Introduction and importance: An overlap syndrome is a condition when there is coexistence of two or more autoimmune connective tissue disease, which is very rare and diagnostically challenging. Dermatomyositis is an autoimmune condition that presents with skin manifestations, progressive muscular weakness, and inflammation. Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune condition mainly affecting skin, joints, kidneys, and brain. Early recognition and therapeutic intervention are necessary in overlap syndromes to prevent the patient from having severe cardiopulmonary problems. Case presentation: This is a case of a 32-year-old woman diagnosed with SLE who developed progressive muscle weakness (3/5 strength proximally) and a distinctive rash, classic signs of dermatomyositis from last 2 months. Laboratory tests have shown elevated creatine kinase (3500 U/l), positive ANA (1:640), anti-dsDNA, and anti-Jo-1 antibodies, along with visible myopathic alterations on electromyographs; unique results on muscle and skin biopsies were all confirmed by investigations. Clinical discussion: After confirming the diagnosis of dermatomyositis, the patient condition was managed by high dose corticosteroids (prednisolone 1 mg/kg/day), intravenous immunoglobulin for severe muscle weakness, methotrexate, high-dose corticosteroids, and physical therapy. Conclusion: This case highlights the complexity of diagnosis in distinguishing the true dermatomyositis from SLE associated inflammatory myopathy in young adults. It emphasizes the importance of early recognition of DM-SLE overlap syndrome through targeted investigations integrating clinical, serological, and histopathological assessment; that can alter the disease trajectory. The case emphasizes the importance of maintaining high clinical suspicion in patients with autoimmune diseases while guiding the immunosuppressive therapy.
- Open Access
- 3 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (40) , e44837
Prourokinase for acute ischemic stroke: A meta-analysis of randomized controlled trials
Background: Use of current thrombolytic agents, such as alteplase, is limited by risks such as intracranial hemorrhage, short half-life, and complex dosing regimens. These drawbacks hinder their optimal use in ischemic stroke treatment. Prourokinase (Pro-UK), with its fibrin specificity and favorable safety profile, offers a promising alternative. This meta-analysis aims to comprehensively evaluate its efficacy and safety in improving clinical outcomes for stroke patients. Methods: A systematic literature review was conducted across PubMed, Scopus, and Web of Science from 1989 to 2024 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data analysis and visualization were performed using ReviewManager (RevMan) with a random-effects model. Risk of bias was assessed using the Cochrane tool, publication bias using Egger’s test, and cumulative meta-analysis via trial sequential analysis. Results: A total of 5 randomized controlled trials comprising 3812 participants were included in this meta-analysis. The pooled analysis revealed that Pro-UK did not result in a statistically significant improvement in clinical outcomes among stroke patients, as measured by the National Institutes of Health Stroke Scale at 24 hours (mean difference = 0.06; 95% confidence interval [CI]: −0.09 to 0.21), the modified Rankin Scale (risk ratio [RR] = 0.99; 95% CI: 0.96–1.03), and the Barthel index (RR = 1.00; 95% CI: 0.99–1.01). Additionally, while there was a trend toward a reduction in systemic intracranial hemorrhage in the Pro-UK group, this finding did not reach statistical significance (RR = 0.86; 95% CI: 0.43–1.72). Conclusion: While Pro-UK offers a theoretical advantage in reducing systemic bleeding due to its clot-specific action, current evidence does not significantly improve key clinical outcomes. The limited number and heterogeneity of existing randomized controlled trials underscore the need for more robust, large-scale trials to confirm its safety and efficacy in acute ischemic stroke.
- 3 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (40) , e44837
Open AccessProurokinase for acute ischemic stroke: A meta-analysis of randomized controlled trials
Background: Use of current thrombolytic agents, such as alteplase, is limited by risks such as intracranial hemorrhage, short half-life, and complex dosing regimens. These drawbacks hinder their optimal use in ischemic stroke treatment. Prourokinase (Pro-UK), with its fibrin specificity and favorable safety profile, offers a promising alternative. This meta-analysis aims to comprehensively evaluate its efficacy and safety in improving clinical outcomes for stroke patients. Methods: A systematic literature review was conducted across PubMed, Scopus, and Web of Science from 1989 to 2024 in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data analysis and visualization were performed using ReviewManager (RevMan) with a random-effects model. Risk of bias was assessed using the Cochrane tool, publication bias using Egger’s test, and cumulative meta-analysis via trial sequential analysis. Results: A total of 5 randomized controlled trials comprising 3812 participants were included in this meta-analysis. The pooled analysis revealed that Pro-UK did not result in a statistically significant improvement in clinical outcomes among stroke patients, as measured by the National Institutes of Health Stroke Scale at 24 hours (mean difference = 0.06; 95% confidence interval [CI]: −0.09 to 0.21), the modified Rankin Scale (risk ratio [RR] = 0.99; 95% CI: 0.96–1.03), and the Barthel index (RR = 1.00; 95% CI: 0.99–1.01). Additionally, while there was a trend toward a reduction in systemic intracranial hemorrhage in the Pro-UK group, this finding did not reach statistical significance (RR = 0.86; 95% CI: 0.43–1.72). Conclusion: While Pro-UK offers a theoretical advantage in reducing systemic bleeding due to its clot-specific action, current evidence does not significantly improve key clinical outcomes. The limited number and heterogeneity of existing randomized controlled trials underscore the need for more robust, large-scale trials to confirm its safety and efficacy in acute ischemic stroke.
- Open Access
- 31 August 2025
- Published by Biomedical Informatics in Bioinformation
- Vol. 21 (08) , 2747-2752
Pulmonary rehabilitation efficacy on quality of life and functional capacity in interstitial lung disease
The impact of pulmonary rehabilitation (PR) on health-related quality of life (HRQOL), functional capacity and compliance in patients with interstitial lung disease (ILD) is of interest. Ten patients participated in a 3-month PR program, which significantly improved 6-minute walk test (6MWT) distance and St. George’s Respiratory Questionnaire (SGRQ) scores. High compliance (90%) was observed, with improvements in breathlessness and recovery perception. Thus, we show that PR is effective in enhancing HRQOL and functional capacity in ILD patients. Larger studies are needed to confirm these findings and assess long-term benefits.
- 31 August 2025
- Published by Biomedical Informatics in Bioinformation
- Vol. 21 (08) , 2747-2752
Open AccessPulmonary rehabilitation efficacy on quality of life and functional capacity in interstitial lung disease
The impact of pulmonary rehabilitation (PR) on health-related quality of life (HRQOL), functional capacity and compliance in patients with interstitial lung disease (ILD) is of interest. Ten patients participated in a 3-month PR program, which significantly improved 6-minute walk test (6MWT) distance and St. George’s Respiratory Questionnaire (SGRQ) scores. High compliance (90%) was observed, with improvements in breathlessness and recovery perception. Thus, we show that PR is effective in enhancing HRQOL and functional capacity in ILD patients. Larger studies are needed to confirm these findings and assess long-term benefits.